For example, combining vorinostat with gemcitabine has shown considerable clinical success in overcoming the epigenetic repression of key drug transporters such as hENT1 in gemcitabine-resistant pancreatic cancer [101]. This evidence concerns the gene SLC29A1 and pancreatic neoplasm.